Efficacy Safety post exposure prophylaxis VaillTM CoViTRAP COVID-19 Efficacy Safety post exposure prophylaxis VaillTM CoViTRAP COVID-19 infection
Conditions
Interventions
VaillTM CoViTRAP 2 puffs intranasal q 8 hours continuously in seven days. ,0.9% Normal saline 2 puffs intranasal q 8 hours continuously in seven days.
VaillTM CoViTRAP,Placebo
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age > 18 years 2. High risk or close contact with COVID-19 infection patient within 72 hours 3. Result of ATK Lysun COVID-19 Antigen Rapid Test Device (Colloidal Gold) is negative on enrollment day 4. No history of COVID-19 infection within 3 months 5. Sign inform consent form
Exclusion criteria
Exclusion criteria: 1. Pregnancy 2. Unacceptable to sign inform consent form 3. History of sever allergic reaction to component of VaillTM CoViTRAP
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy 7 days ATK negative | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety 7 days side effect reports | — |
Countries
Thailand
Contacts
Public ContactWannada Laisuan
Ramathibodi Hospital, Mahidol university
Outcome results
None listed